Chemomab Therapeutics Ltd. (CMMB) annual cash flow statement — 11-year operating, investing & financing history
| Cash from Operations | -11.22M | -15.46M | -23.55M | -20.29M | -12.38M | -12.8M | -16.51M | -14.18M | -8.58M | -3.74M | -7.38M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 27.43% | 34.36% | -16.07% | -63.86% | 3.27% | 22.47% | -16.47% | -65.21% | -129.73% | 49.39% | - |
| Net Income | -9.07M | -14.01M | -24.16M | -27.54M | -12.49M | -11.69M | -27.21M | -13.75M | -9.88M | -4.75M | -7.5M |
| Depreciation & Amortization | 70.56K | 53.25K | 66.83K | 57.77K | 34.02K | 80.56K | 281.91K | 65.78K | 51.4K | 40.77K | 26.25K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 635K | 619.93K | 1.49M | 3.2M | 2.02M | 223.56K | 5.79M | 2.92M | 958.38K | 464.21K | 376.5K |
| Working Capital Changes | -2.86M | -2.12M | -945.56K | 3.99M | -1.95M | -1.41M | 4.63M | -3.41M | 291.24K | 508.38K | -283.08K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 2.31M | -3.48M | 205.58K | 116.84K | -568.23K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -178.4K | 150.71K | -1.17M | 350.62K | 1.18M | -198.38K | 1.08M | 286.07K | 44.34K | -492.44K | 423.08K |
| Cash from Investing | 5.43M | 2.31M | 15.84M | 19.46M | -45.22M | 102.72K | -95.31K | -212.31K | -34.26K | 77.89K | 1.12M |
| Capital Expenditures | -3.02K | 0 | -2.99K | -67.73K | -239.16K | -34.24K | -95.31K | -212.31K | -34.26K | -76.06K | -87.24K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 136.95K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 7.21M | 9.91M | 3.49M | -804.84K | 61.12M | 299.08K | 26.71M | 20.55M | 5.28M | 6.06M | 4.47M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.94K | 0 | 0 | 0 |
| Equity Issued (Net) | 7.21M | 9.91M | 3.49M | 408.39K | 58.69M | 0 | 26.71M | 20.54M | 5.28M | 6.06M | 4.59M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -1.21M | 2.43M | 299.08K | 0 | 0 | 0 | 0 | -115.03K |
| Net Change in Cash | 1.42M | -3.22M | -4.23M | -47.57M | 55.77M | -12.18M | 10.06M | 6.06M | -3.11M | 2.35M | -2.11M |
| Free Cash Flow | -11.22M | -15.46M | -23.55M | -20.36M | -12.62M | -12.84M | -16.61M | -14.39M | -8.62M | -3.81M | -7.47M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 27.41% | 34.37% | -15.69% | -61.29% | 1.66% | 22.71% | -15.41% | -67.02% | -126.04% | 48.96% | - |
| FCF per Share | -1.76 | -3.44 | -8.02 | -7.16 | -4.87 | -27.68 | -38.57 | -91.11 | -763.71 | -56.12 | -131.19 |
| FCF Conversion (FCF/Net Income) | 1.25x | 1.11x | 0.97x | 0.73x | 0.99x | 2.15x | 0.61x | 1.03x | 0.88x | 0.79x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CMMB stock.
Chemomab Therapeutics Ltd. (CMMB) generated $-11.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Chemomab Therapeutics Ltd. (CMMB) reported negative free cash flow of $11.2M in 2025, indicating capital requirements exceeded cash from operations.
Chemomab Therapeutics Ltd. (CMMB) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.